A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)

Cliniques Universitaires Saint-Luc, Brussels

UMHAT 'Tsaritsa Yoanna - ISUL', EAD, Sofia

UZ Leuven, Leuven

"UMHAT Sv. Georgi, EAD", Plovdiv

Hospital Universitari Vall d'Hebron, Barcelona

Hôpital de la Timone, Marseille

Children's National Medical Center, Washington D.C.

Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico, Milan

CHU Besançon - Hôpital Jean Minjoz, Besançon

Hospital Universitario La Paz, Madrid

CHU de Toulouse - Hôpital Purpan, Toulouse

Ospedale San Bortolo di Vicenza, Vicenza

Dayton Children's Hospital, Dayton

Hospital Universitari i Politecnic La Fe, Valencia

Indiana Hemophilia and Thrombosis Center, Indianapolis

Childrens Hospital of Michigan, Detroit

University of Iowa Children's Hospital, Iowa City

Universitaetsklinikum Bonn AoeR, Bonn

Blood Center of Southeast Wisconsin, Milwaukee

Hemostase Clinique - Institut Cœur-Poumons (4eme étage aile est), Lille

Rush University Medical Center, Chicago

Hôpital Necker - Enfants Malades, Paris

Cook Children's Medical Center, Fort Worth

Gulf States Hemophilia and Thrombophilia Center, Houston

El Paso Children's Hospital, El Paso

University of Colorado Hemophilia & Thrombosis Center, Aurora

Azienda Ospedaliera Pediatrica Santobono Pausillipon, Napoli

Center for Inherited Blood Disorders, Orange

Children's & Women's Health Centre of British Columbia, Vancouver

McMaster Children's Hospital, Hamilton

The Hospital for Sick Children, Toronto

Nagoya University Hospital, Nagoya

St. Marianna University School of Medicine Hospital, Kawasaki

Nara Medical University Hospital, Kashihara-shi

St Thomas' Hospital, London

John Radcliffe Hospital, Oxford

Royal Hospital for Children, Glasgow